Journal of Current Medical Research and Practice

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 2  |  Issue : 3  |  Page : 157--161

Prevalence of ovarian hyperstimulation in normal responders receiving letrozole in assisted reproductive technology: A randomized controlled trial


E Ihab1, M Alaa Eldeen1, A Elwany2, Amr Sh3,  
1 IVF Unit, Department of Obstetrics and Gynecology, Women's Health Hospital, Assiut University, Assiut, Egypt
2 OB-GYN Department, Assiut University, Assiut, Egypt
3 Assisted Reproductive Technology Unit, Department of Obstetrics and Gynecology, Women's Health Hospital, Assiut University, Assiut, Egypt

Correspondence Address:
A Elwany
OB&GYN, Assisted Reproductive Technology Unit, Department of Obstetrics and Gynecology, Women's Health Hospital, Assiut University, Assiut
Egypt

Abstract

Introduction The use of letrozole, a selective aromatase inhibitor, induces follicular maturation. Randomized controlled trials addressing the utility of letrozole in normal responders are few. We evaluated whether incorporation of letrozole could be effective in decreasing ovarian hyperstimulation syndrome (OHSS) in normal responders undergoing intracytoplasmic sperm injection cycles. Objective The objective of this study was to compare the aromatase inhibitor (letrozole) with low-dose gonadotropins versus the standard long protocol for controlled OHSS in normal responder women undergoing intracytoplasmic sperm injection in terms of OHSS. Patients and methods This was a randomized noninferiority clinical trial registered in clinicaltrials.gov (NCT02429999). This study was conducted in Assiut University Fertility Center, from January 2015 to April 2016, and included 61 normal responder women randomized in a 1: 2 ratio. Twenty-one women (study group) received letrozole at a 10 mg daily dose from days 3 to 7 together with follicle-stimulating hormone (FSH) 75 IU/day from day 5. Gonadotropin-releasing hormone antagonist (orgalutran 0.25) is given when the follicle size is equal to 14 mm until human chorionic gonadotropin injection. Forty women (control group) received 0.1 mg decapeptyl from day 21 in the preceding cycle and continuously stimulated by FSH (150–225 IU/day) from day 2. The total dose of FSH received, number of mature oocytes, good-quality embryos, and OHSS were evaluated in both groups. Statistical analysis was done using Student's t-test and χ2-test when appropriate. Results Comparable rates for maturation index, fertilization, and good-quality embryos were yielded by both groups. The incidence of OHSS was significantly lower in the letrozole group compared with the long protocol group (P = 0.03). Conclusion Minimal stimulation protocol using letrozole with gonadotropins may form an effective tool to decrease the incidence of OHSS in in-vitro fertilization cycles in normal responding women.



How to cite this article:
Ihab E, Eldeen M A, Elwany A, Sh A. Prevalence of ovarian hyperstimulation in normal responders receiving letrozole in assisted reproductive technology: A randomized controlled trial.J Curr Med Res Pract 2017;2:157-161


How to cite this URL:
Ihab E, Eldeen M A, Elwany A, Sh A. Prevalence of ovarian hyperstimulation in normal responders receiving letrozole in assisted reproductive technology: A randomized controlled trial. J Curr Med Res Pract [serial online] 2017 [cited 2018 Sep 21 ];2:157-161
Available from: http://www.jcmrp.eg.net/text.asp?2017/2/3/157/234922


Full Text

 Introduction



It is well known that ovarian hyperstimulation syndrome (OHSS) is often induced by ovarian stimulation protocols in in-vitro fertilization (IVF). Prevention of OHSS is the main consideration when performing this procedure.

OHSS remains a lethal iatrogenic complication of the early luteal phase and/or early pregnancy after ovarian stimulation [1]. OHSS has been classified based on severity (mild, moderate, severe, and critical). In addition, based on the time of occurrence, OHSS has been classified into early (<9 days) and late. Moderate or severe OHSS affects 2–3% of patients, whereas milder forms may develop in 20–30% of all IVF cycles. The significant risks are associated with moderate/severe OHSS, which could lead to acute renal insufficiency, acute respiratory distress syndrome, and venous thromboembolism [2].

Pathophysiological changes of OHSS that underlie these events include arteriolar vasodilatation and increased capillary permeability. This facilitates a shift in fluid from the intravascular to the extravascular compartment and the induction of a state of hypovolemic hyponatremia with hemoconcentration. Although various systemic and local vasoactive mediators contribute to the pathogenesis of OHSS, vascular endothelial growth factor appears to be critical to the development of the condition [3].

The current work is aimed at evaluating the efficacy of letrozole (LTZ) as a modality for minimal ovarian stimulation aiming to decrease OHSS.

 Patients and Methods



Study design

The present study is a randomized clinical noninferiority trial. The study was conducted at Assisted Reproductive Technology (ART) Unit of Women's Health Hospital, Assiut University, Assiut, Egypt, from January 2015 to April 2016. The protocol of the study has been approved by the Ethical Review Board of Faculty of Medicine, Assiut University. This study was registered in the website clinicaltrials.gov (NCT02429999, http://www.clinicaltrials.gov).

Women attending the ART Unit of Women's Health Hospital, Assiut University, were considered for enrollment. In the study period, 120 eligible women were selected from the clinic of the ART Unit. They were randomized by sealed envelope into two groups. Group 1 included 80 women who received long midluteal protocol, whereas group 2 included 40 women who received minimal stimulation protocol (LTZ/gonadotropin). Eligible women were counseled and offered to join the study after obtaining written informed consent. The consent forms were signed after thorough discussion with the couples and explanation of the study purpose, interventions, outcomes, and adverse events.

Enrollment criteria

Women were included if they 20-35 years old, with a BMI of 18–29 kg/m 2, infertile with an indication for IVF [including unexplained infertility, tubal factor, and male factor (including concentrations down to 5–10 million sperms/ml)], with anticipated adequate ovarian response, antral follicle count more than five follicles in one ovary, and/or anti-Müllerian hormone (AMH) more than 1 ng/ml [4].

We excluded patients with endometriosis and poor ovarian response (POR). In addition, we excluded poor responders based on Bologna criteria. At least two of the following three criteria had to be present to establish the definition of poor responder: (i) advanced maternal age (>40 years) or any other risk factor for POR; (ii) a previous POR (≤3 oocytes with a conventional stimulation protocol); (iii) an abnormal ovarian reserve test (i.e. antral follicle count less than 5–7 follicles or AMH [5].

Randomization

Allocation of participants in the two groups was intentionally made unequal with a lesser number of women treated with LTZ, as this was a relatively new drug in the field of controlled OHSS in normal responders. Among most of the studies of controlled ovarian stimulation, only two studies used LTZ in normal responders. The randomization ratio of LTZ/gonadotropins protocol to the gonadotropin-releasing hormone (GnRH) antagonist protocol was taken to be 1: 2. Sequentially numbered sealed envelopes were prepared and provided by the study coordinator, according to random-number tables.

Interventions

Group 1 (control group) received 0.1 mg decapeptyl (triptorelin; Ipsen Pharma, Barcelona, Spain) from day 21 in the previous cycle and continuously stimulated by follicle-stimulating hormone (FSH) (150–225 IU/day) from day 2, whereas group 2 received (study group) LTZ (Jiangsu Hengrui Medicine, Lianyungang, China) 10 mg daily from days 3 to 7 and FSH 75 IU/day from day 5 continuously. GnRH antagonist (orgalutran 0.25 mg ganirelix; N.V. Organon, Oss, The Netherlands) is given when the follicle size is equal to 14 mm until human chorionic gonadotropin injection.

Outcome measures

The incidence of OHSS was the primary outcome measure of this study. Mild OHSS was diagnosed by mild abdominal pain, abdominal bloating, and ovarian size usually less than 8 cm. Moderate OHSS was concluded after moderate abdominal pain, nausea and vomiting, ultrasound evidence of ascites, and ovarian size usually 8–12 cm, whereas severe OHSS was suspected if there is clinical ascites (occasionally hydrothorax), oliguria, hemoconcentration, hematocrit more than 45%, hypoproteinemia, and ovarian size usually more than 12 cm. Critical OHSS is a condition with tense ascites or large hydrothorax, hematocrit more than 55%, white cell count more than 25 000/ml, oligo/anuria, thromboembolism, and acute respiratory distress syndrome [6].

The total dose of FSH injection, maturation index, good-quality embryos, as well as endometrial thickness at the time of human chorionic gonadotropin trigger, has been evaluated in both groups as secondary outcomes.

Sample size

According to Mukherjee et al. [7], the pregnancy rate was increased in the LTZ–FSH group (36%) compared with that in the control group (33%). We calculated the sample size at α equal to 0.05, 95% confidence interval of 1.96 for normal distribution, and statistical power of 80% Statistical analysis was performed using SPSS version 24 STATA software, version 13. Estimated sample size was 120 patients distributed in a 1: 2 ratio [8].

Statistical analysis

Statistical analysis was performed using SPSS, version 24. First, Shapiro–Wilk's test was used in the tested population as a test of normality for continuous variables. Parametric variables were expressed as mean ± SD. χ2 and Fisher's exact tests were used to compare proportions as appropriate. Interim analysis will be done once half of the sample size is achieved as part of the periodic assessment of the ART Unit results.

 Results



Forty women received the standard long protocol, whereas 21 underwent stimulation by LTZ. The present work was conducted as a noninferiority trial, but the results of LTZ were the lowest among the results of different induction protocols used in our university ART Unit through the study period as demonstrated by the periodic follow-up of the ART Unit results. Therefore, we performed an interim analysis because of the suboptimal results and the trial was stopped after enrolling half of the sample size. Details are shown in [Figure 1].{Figure 1}

Both groups were comparable as regards age, BMI, duration of infertility, antral follicle count, and hormonal profile; estradiol (E2), AMH, FSH, and luteinizing hormone were also comparable, as shown in [Table 1] and [Table 2]. As shown in [Table 3], women in the LTZ group significantly received lower doses of gonadotropins; approximately more than half of the dose was reduced in the LTZ group. In addition, women in the long protocol group achieved almost double the level of peak E2 measured at the day of trigger. The use of long protocol was also associated with a significant increase in the number of oocytes retrieved and fertilized. Endometrial thickness was higher also in the long protocol group. However, no significant difference (P > 0.05) was observed in oocyte maturation index between groups. There was no significant difference (P > 0.05) between the two protocols as regards the fertilization rate and the incidence of total fertilization failure, and canceled cycles. However, the incidence of OHSS was significantly higher in the long protocol group as reported in [Table 4] and [Figure 2].{Table 1}{Table 2}{Table 3}{Table 4}{Figure 2}

 Discussion



The current work is basically a comparative effectiveness research comparing two interventional therapies in normal responder women as a part of controlled ovarian hyperstimulation. The study is aimed at evaluating the efficacy of LTZ as a modality for minimal ovarian stimulation aiming to decrease OHSS.

The two main complications associated with the use of assisted reproduction techniques, OHSS and multiple pregnancies, could be eliminated by milder ovarian stimulation protocols. In comparison with current approaches, the aim of mild stimulation is to develop safer and more patient-friendly protocols in which the risks of the treatment as a whole are minimized. 'Mini-IVF' has several advantages over conventional IVF protocols, including less medication and fewer injections, producing fewer eggs, but eggs of higher quality [9].

LTZ has been evaluated before for controlled ovarian stimulation with intrauterine insemination. Investigators found that the primary advantage of LTZ use was reduction in doses of gonadotropins, as well as in the chance of multiple pregnancies and OHSS [10].

LTZ has also been tried for ovarian stimulation in IVF/intracytoplasmic sperm injection cycles. However, very few trials with limited number of patients are available. Five randomized trials, with a total of 265 patients, dealt with poor responders. They were randomized to receive LTZ combined with gonadotropins or gonadotropins alone, in an antagonist or agonist protocol. The gonadotropin dose used was consistently lower in the LTZ cotreatment group in all trials [11],[12].

The role of aromatase inhibitors during luteal phase of stimulated IVF cycle is to reduce circulating E2 levels, thus potentially leading to reducing OHSS risk [13],[14].

We found in our results that women in the LTZ group had the advantages of LTZ use; they reported reduction in total received dose and hence reduction in OHSS compared with the long agonist protocol group.

Women who received agonist protocol in the present work showed significantly increased incidence of OHSS (10 vs. 0%). It has been reported that the incidence of OHSS is much higher in patients who use GnRH agonists in a long protocol [15].

In accordance with our results, Mukherjee et al. [7] reported similar significant reduction in OHSS in the LTZ group. In addition to the danger of OHSS on patient life, this complication contributes in increasing the overall cost of the IVF cycle.

 Conclusion



The use of LTZ in normal responders reduces unnecessary side effects such as OHSS and multiple pregnancies and reduces their cost implications.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016; 106:1634–1647.
2Humaidan P, Nelson SM, Devroey P, Coddington CC, Schwartz LB, Gordon K, et al. Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. Hum Reprod 2016;31:1997–2004.
3Soares SR, Gomez R, SimonC, Garcia-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 2008;14:321–333.
4Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: Comparison with the antral follicle count. Fertil Steril 2009;91:705–714.
5Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. On behalf of the ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26:1616–1624.
6Royal College of Obstetricians and Gynaecologists. Ovarian hyperstimulation syndrome, management (Green-top Guideline No. 5); 2016. Available at: https://www. rcogorguk/en/guidelines-research-services/guidelines/gtg5/. [Last accessed on 2017 Mar 12].
7Mukherjee S, Sharma S, Chakravarty BN. Comparative evaluation of pregnancy outcome in gonadotrophin-clomiphene combination vs clomiphene alone in polycystic ovarian syndrome and unexplained infertility – A prospective clinical trial. J Hum Reprod Sci 2012;5:170–174.
8Jones S, Carley S, Harrison M. An introduction to power and sample size estimation. Emerg Med J 2003;20:453.
9Allahbadia GN, Morimoto Y. Ovarian stimulation protocols. Heidelberg; New York; Dordrecht; London: Springer; 2016.
10Abu Hashim H, El Rakhawy M, AbdElaal I. Randomized comparison of superovulation with letrozole vs. clomiphene citrate in an IUI program for women with recently surgically treated minimal to mild endometriosis. Acta Obstet Gynecol Scand 2012;91:338–345.
11Garcia-Velasco JA, Moreno L, Pacheco A, Guillen A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril 2005;84:82–87.
12Ozmen B, Sonmezer M, Atabekoglu CS, Olmus H. Use of aromatase inhibitors in poor-responder patients reseiving GnRH antagonist protocols. Reprod Biomed Online 2009;19:478–485.
13Fatemi HM, Popovic-Todorovic B, Donoso P, Papanikolaou E, Smitz J, Devroey P. Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reprod Biomed Online 2008;17:307–311.
14Garcia-Velasco JA, Quea G, Piro M, Mayoral M, Ruiz M, Toribio M, et al. Letrozole administration during the luteal phase after ovarian stimulatin impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril 2009;92:222–225.
15Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:883–896.